Recruiting
Phase 1
Phase 2

Adenosine 2A Receptor Antagonism

Sponsor:

University of Florida

Code:

NCT05377424

Conditions

ALS

Eligibility Criteria

Sex: All

Age: 21 - 70+

Healthy Volunteers: Accepted

Interventions

Consume 20mg of istradefylline

Low Oxygen therapy

Placebo counterpart to the istradefylline drug

SHAM counterpart to low oxygen therapy.

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-06-01. This information was provided to ClinicalTrials.gov by University of Florida on 2024-11-14.